{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:06:38Z","timestamp":1767650798576},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bial"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40120-022-00371-7","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T03:39:21Z","timestamp":1655350761000},"page":"1409-1425","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Opicapone as an Add-on to Levodopa in Patients with Parkinson\u2019s Disease Without Motor Fluctuations: Rationale and Design of the Phase\u00a0III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial"],"prefix":"10.1007","volume":"11","author":[{"given":"Joaquim J.","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[]},{"given":"Fabrizio","family":"Stocchi","sequence":"additional","affiliation":[]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Francisco","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"371_CR1","doi-asserted-by":"crossref","unstructured":"Greenland JC, Barker RA. Chapter 6: the differential diagnosis of Parkinson\u2019s Disease. In: Stoker TB, Greenland JC, editors. Parkinson\u2019s disease: pathogenesis and clinical aspects [Internet]. Brisbane: Codon; 2018.","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch6"},{"key":"371_CR2","doi-asserted-by":"publisher","unstructured":"Lebouvier T, Chaumette T, Paillusson S, et al. The second brain and Parkinson's disease. Eur J Neurosci. 2009;30(5):735\u201341. https:\/\/doi.org\/10.1111\/j.1460-9568.2009.06873.x.","DOI":"10.1111\/j.1460-9568.2009.06873.x"},{"key":"371_CR3","doi-asserted-by":"publisher","unstructured":"GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939\u201353. https:\/\/doi.org\/10.1016\/S1474-4422(18)30295-3.","DOI":"10.1016\/S1474-4422(18)30295-3"},{"key":"371_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neubiorev.2015.11.014","volume":"61","author":"JM van Uem","year":"2016","unstructured":"van Uem JM, Marinus J, Canning C, et al. Health-related quality of life in patients with Parkinson\u2019s disease\u2014a systematic review based on the ICF model. Neurosci Biobehav Rev. 2016;61:26\u201334. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.11.014","journal-title":"Neurosci Biobehav Rev"},{"key":"371_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/jep.s267032","volume":"13","author":"T M\u00fcller","year":"2021","unstructured":"M\u00fcller T. Experimental dopamine reuptake inhibitors in Parkinson\u2019s disease: a review of the evidence. J Exp Pharmacol. 2021;13:397\u2013408. https:\/\/doi.org\/10.2147\/jep.s267032.","journal-title":"J Exp Pharmacol"},{"key":"371_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/cia.s6456","volume":"5","author":"W Poewe","year":"2010","unstructured":"Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson\u2019s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229\u201338. https:\/\/doi.org\/10.2147\/cia.s6456.","journal-title":"Clin Interv Aging"},{"issue":"2","key":"371_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-012-0024-7","volume":"52","author":"L Almeida","year":"2013","unstructured":"Almeida L, Rocha JF, Falc\u00e3o A, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet. 2013;52(2):139\u201351. https:\/\/doi.org\/10.1007\/s40262-012-0024-7.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"371_CR8","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1021\/jm1001524","volume":"53","author":"LE Kiss","year":"2010","unstructured":"Kiss LE, Ferreira HS, Torr\u00e3o L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53(8):3396\u2013411.","journal-title":"J Med Chem"},{"issue":"12","key":"371_CR9","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/mds.23875","volume":"26","author":"A Antonini","year":"2011","unstructured":"Antonini A, Martinez-Martin P, Chaudhuri RK, et al. Wearing-off scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2011;26(12):2169\u201375. https:\/\/doi.org\/10.1002\/mds.23875.","journal-title":"Mov Disord"},{"issue":"10","key":"371_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/mds.28215","volume":"35","author":"CWCP Olanow","year":"2020","unstructured":"Olanow CWCP, Obeso JA. Continuous dopaminergic stimulation as a treatment for Parkinson\u2019s disease: current status and future opportunities. Mov Disord. 2020;35(10):1731\u201344.","journal-title":"Mov Disord"},{"key":"371_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CWOJ Olanow","year":"2006","unstructured":"Olanow CWOJ, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientifi c rationale and clinical implications. Lancet Neurol. 2006;5:677\u201387.","journal-title":"Lancet Neurol"},{"issue":"6","key":"371_CR12","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","volume":"38","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Pahwa R, et al. The long-term impact of levodopa\/carbidopa intestinal gel on \u2019off\u2019-time in patients with advanced parkinson\u2019s disease: a systematic review. Adv Ther. 2021;38(6):2854\u201390. https:\/\/doi.org\/10.1007\/s12325-021-01747-1.","journal-title":"Adv Ther"},{"issue":"1 Suppl 1","key":"371_CR13","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1212\/wnl.62.1_suppl_1.s56","volume":"62","author":"F Stocchi","year":"2004","unstructured":"Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson\u2019s disease. Neurology. 2004;62(1 Suppl 1):S56-63. https:\/\/doi.org\/10.1212\/wnl.62.1_suppl_1.s56.","journal-title":"Neurology"},{"issue":"8","key":"371_CR14","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s10072-020-04303-x","volume":"41","author":"X Liao","year":"2020","unstructured":"Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Levodopa\/carbidopa\/entacapone for the treatment of early Parkinson\u2019s disease: a meta-analysis. Neurol Sci. 2020;41(8):2045\u201354. https:\/\/doi.org\/10.1007\/s10072-020-04303-x.","journal-title":"Neurol Sci"},{"issue":"1","key":"371_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18\u201327. https:\/\/doi.org\/10.1002\/ana.22060.","journal-title":"Ann Neurol"},{"key":"371_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2047-9158-4-4","volume":"4","author":"F Stocchi","year":"2015","unstructured":"Stocchi F, Vacca L, Radicati FG. How to optimize the treatment of early stage Parkinson\u2019s disease. Transl Neurodegener. 2015;4:4. https:\/\/doi.org\/10.1186\/2047-9158-4-4.","journal-title":"Transl Neurodegener"},{"key":"371_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/dnnd.s256722","volume":"11","author":"L Azevedo Kauppila","year":"2021","unstructured":"Azevedo Kauppila L, Pimenta Silva D, Ferreira JJ. Clinical utility of opicapone in the management of parkinson\u2019s disease: a short review on emerging data and place in therapy. Degener Neurol Neuromuscul Dis. 2021;11:29\u201340. https:\/\/doi.org\/10.2147\/dnnd.s256722.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"2","key":"371_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/s1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154\u201365. https:\/\/doi.org\/10.1016\/s1474-4422(15)00336-1.","journal-title":"Lancet Neurol"},{"issue":"2","key":"371_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74(2):197\u2013206. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4703.","journal-title":"JAMA Neurol"},{"key":"371_CR20","unstructured":"European Medicines Agency. Ongentys\u00ae Summary of Product Characteristics, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ongentys-epar-product-information_en.pdf. Accessed 20 Jan 2022."},{"key":"371_CR21","unstructured":"Food and Drug Administration. Ongentys\u00ae Highlights of Prescribing Information, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212489s000lbl.pdf. Accessed 20 Jan 2022."},{"issue":"8","key":"371_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248\u201366. https:\/\/doi.org\/10.1002\/mds.27372.","journal-title":"Mov Disord"},{"issue":"7","key":"371_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/ene.13914","volume":"26","author":"JJ Ferreira","year":"2019","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson\u2019s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019;26(7):953\u201360. https:\/\/doi.org\/10.1111\/ene.13914.","journal-title":"Eur J Neurol"},{"key":"371_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.754016","author":"J-F Rocha","year":"2021","unstructured":"Rocha J-F, Ebersbach G, Lees A, et al. The added benefit of opicapone when used early in Parkinson\u2019s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and -II. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2021.754016.","journal-title":"Front Neurol"},{"issue":"10","key":"371_CR25","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/mds.25122","volume":"27","author":"CG Goetz","year":"2012","unstructured":"Goetz CG, Stebbins GT, Tilley BC. Calibration of unified Parkinson\u2019s disease rating scale scores to Movement Disorder Society-unified Parkinson\u2019s disease rating scale scores. Mov Disord. 2012;27(10):1239\u201342. https:\/\/doi.org\/10.1002\/mds.25122.","journal-title":"Mov Disord"},{"issue":"5","key":"371_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342. https:\/\/doi.org\/10.1212\/wnl.17.5.427.","journal-title":"Neurology"},{"issue":"9","key":"371_CR27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020\u20138. https:\/\/doi.org\/10.1002\/mds.20213.","journal-title":"Mov Disord"},{"key":"371_CR28","unstructured":"Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson\u2019s disease. In: Gilingham FH, Donaldson MC, editors. Edinburgh: Churchill Livingstone; 1969."},{"issue":"6","key":"371_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","volume":"73","author":"KR Chaudhuri","year":"2002","unstructured":"Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson\u2019s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629\u201335. https:\/\/doi.org\/10.1136\/jnnp.73.6.629.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"371_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kohnen R, H\u00f6gl B, et al. Parkinson\u2019s disease sleep scale\u2013validation of the revised version PDSS-2. Mov Disord. 2011;26(4):644\u201352. https:\/\/doi.org\/10.1002\/mds.23476.","journal-title":"Mov Disord"},{"key":"371_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.sleep.2016.06.026","volume":"24","author":"ML Muntean","year":"2016","unstructured":"Muntean ML, Benes H, Sixel-D\u00f6ring F, et al. Clinically relevant cut-off values for the Parkinson\u2019s Disease Sleep Scale-2 (PDSS-2): a validation study. Sleep Med. 2016;24:87\u201392. https:\/\/doi.org\/10.1016\/j.sleep.2016.06.026.","journal-title":"Sleep Med"},{"issue":"13","key":"371_CR32","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901\u201311. https:\/\/doi.org\/10.1002\/mds.21596.","journal-title":"Mov Disord"},{"issue":"3","key":"371_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/bf02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease. Qual Life Res. 1995;4(3):241\u20138. https:\/\/doi.org\/10.1007\/bf02260863.","journal-title":"Qual Life Res"},{"issue":"6","key":"371_CR34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/01.Wnf.0000232277.68501.08","volume":"29","author":"M Stacy","year":"2006","unstructured":"Stacy M, Hauser R, Oertel W, et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol. 2006;29(6):312\u201321. https:\/\/doi.org\/10.1097\/01.Wnf.0000232277.68501.08.","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"371_CR35","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10111704.","journal-title":"Am J Psychiatry"},{"key":"371_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.psychres.2018.05.006","volume":"265","author":"SR Chamberlain","year":"2018","unstructured":"Chamberlain SR, Grant JE. Minnesota Impulse Disorders Interview (MIDI): validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample. Psychiatry Res. 2018;265:279\u201383. https:\/\/doi.org\/10.1016\/j.psychres.2018.05.006.","journal-title":"Psychiatry Res"},{"key":"371_CR37","unstructured":"Zafar S, Yaddanapudi SS. Parkinson disease. Treasure Island: StatPearls; 2021."},{"issue":"1","key":"371_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/mds.25032","volume":"28","author":"EC Hirsch","year":"2013","unstructured":"Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson\u2019s disease. Mov Disord. 2013;28(1):24\u201330. https:\/\/doi.org\/10.1002\/mds.25032.","journal-title":"Mov Disord"},{"issue":"3","key":"371_CR39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ana.410240303","volume":"24","author":"G Fabbrini","year":"1988","unstructured":"Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson\u2019s disease: central pathophysiological mechanisms. Part I. Ann Neurol. 1988;24(3):366\u201371. https:\/\/doi.org\/10.1002\/ana.410240303.","journal-title":"Ann Neurol"},{"issue":"6","key":"371_CR40","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/mds.27691","volume":"34","author":"KR Chaudhuri","year":"2019","unstructured":"Chaudhuri KR, Jenner P, Antonini A. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson\u2019s disease? Mov Disord. 2019;34(6):816\u20139. https:\/\/doi.org\/10.1002\/mds.27691.","journal-title":"Mov Disord"},{"issue":"1","key":"371_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000117399","volume":"37","author":"G Block","year":"1997","unstructured":"Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa\/levodopa in Parkinson\u2019s disease. A multicenter 5-year study. The CR first study group. Eur Neurol. 1997;37(1):23\u20137. https:\/\/doi.org\/10.1159\/000117399.","journal-title":"Eur Neurol"},{"key":"371_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-020-00187-1","author":"H Reichmann","year":"2020","unstructured":"Reichmann H. Effectiveness and safety of opicapone in Parkinson\u2019s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegen. 2020. https:\/\/doi.org\/10.1186\/s40035-020-00187-1.","journal-title":"Transl Neurodegen"},{"issue":"9","key":"371_CR43","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00228-014-1701-2","volume":"70","author":"JF Rocha","year":"2014","unstructured":"Rocha JF, Falc\u00e3o A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014;70(9):1059\u201371. https:\/\/doi.org\/10.1007\/s00228-014-1701-2.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00371-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:03:42Z","timestamp":1659107022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00371-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["371"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00371-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}